China Petroleum Capital
9 Dongzhimen North Street, Beijing, Dongcheng District, 100007, China
Overview
CNPC Capital is a financial institution that provides house banking, banking, financial leasing, trust, insurance, insurance brokerage, and securities services. It also offers loan services for internet loans, housing mortgage loans, petroleum workers' credit loans, and personal business loans.
- Total investments
- 2
- Lead investments
- 0
- Investments · 12mo
- 0
- Active investors
- 0
Sector focus
- Finance
- Financial Services
- Insurance
Investment portfolio
- Puli Materials
Participated · Series B · Dec 2023
普力材料 develops and manufactures CO2‑based new materials, concentrating on high‑value utilization of carbon dioxide and industrializing negative‑carbon materials. The company focuses on the "U" (utilization) part of CCUS and aims to provide high‑performance polyurethane carbon‑neutral solutions for China. It holds a proprietary CO2 new‑materials polymerization process and its core product is a CO2‑based polycarbonate polyether polyol (PCE). The firm emphasizes CO2 utilization technology as its core competitive advantage. Recently it completed a B+ financing round, raising several tens of millions of RMB. The proceeds are intended for innovative technology R&D and to supplement working capital. Puli Materials develops and manufactures CO2-based new materials with a focus on high-value utilization of carbon dioxide. The company specializes in industrializing negative-carbon new materials and aims to provide high-performance polyurethane carbon-neutral solutions for China. It recently completed nearly ¥200 million in a B round financing. The proceeds are earmarked primarily for construction of a new production line for CO2-based polyols. The funding is intended to expand the company’s production capacity for its CO2-derived materials. No other financial or operating metrics were disclosed in the article.
- CapitalBio Technology
Participated · Equity · Jun 2020
Beijing博奥晶典生物技术有限公司 is a leading domestic provider of gene testing and biochip-based diagnostics with R&D, production, sales and a nationwide third‑party independent medical laboratory service. The company supplies technology and solutions to life sciences research, medical testing, new drug R&D, health management, forensic testing, agriculture/food safety and related fields. It claims the world’s largest original biochip technology platform, has drafted national standards, and holds more than 300 granted patents with a patent conversion rate near 50%. After completing a Pre-IPO financing of over ¥800 million, the company plans to accelerate new product R&D and expand its chip production lines. Management also intends to strengthen sales, marketing and overseas expansion. In addition, the company will initiate share‑reform work and prepare a科创板 (SSE STAR Market) IPO filing.
Team
No current team members are available.